0001209191-14-008201.txt : 20140206 0001209191-14-008201.hdr.sgml : 20140206 20140206204723 ACCESSION NUMBER: 0001209191-14-008201 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20140206 FILED AS OF DATE: 20140206 DATE AS OF CHANGE: 20140206 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARGOS THERAPEUTICS INC CENTRAL INDEX KEY: 0001105533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562110007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 BUSINESS PHONE: 9192876300 MAIL ADDRESS: STREET 1: 4233 TECHNOLOGY DR CITY: DURHAM STATE: NC ZIP: 27704 FORMER COMPANY: FORMER CONFORMED NAME: MERIX BIOSCIENCE INC DATE OF NAME CHANGE: 20000207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Public Joint Stock Co Pharmstandard CENTRAL INDEX KEY: 0001598754 STATE OF INCORPORATION: 1Z FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35443 FILM NUMBER: 14581634 BUSINESS ADDRESS: STREET 1: LIKHACHEVSKY DRIVE STREET 2: 5 "B" CITY: DOLGOPRUDNY STATE: 1Z ZIP: 141701 BUSINESS PHONE: 7 495 970 0032 MAIL ADDRESS: STREET 1: LIKHACHEVSKY DRIVE STREET 2: 5 "B" CITY: DOLGOPRUDNY STATE: 1Z ZIP: 141701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pharmstandard International S.A. CENTRAL INDEX KEY: 0001598762 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35443 FILM NUMBER: 14581635 BUSINESS ADDRESS: STREET 1: 65 BOULEVARD GRANDE DUCHESSE CHARLOTTE CITY: LUXEMBOURG STATE: N4 ZIP: L-1528 BUSINESS PHONE: 352 26449 557 MAIL ADDRESS: STREET 1: 65 BOULEVARD GRANDE DUCHESSE CHARLOTTE CITY: LUXEMBOURG STATE: N4 ZIP: L-1528 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2014-02-06 0 0001105533 ARGOS THERAPEUTICS INC ARGS 0001598762 Pharmstandard International S.A. 27 SOLJENITSYNA STR. MOSCOW 1Z 109004 RUSSIAN FEDERATION 0 0 1 0 0001598754 Public Joint Stock Co Pharmstandard LIKHACHEVSKY DRIVE 5 "B" DOLGOPRUDNY 1Z 1417000 RUSSIAN FEDERATION 0 0 1 0 Series E Preferred Stock Common Stock 4708549 I See footnote The Series E Preferred Stock has no expiration date. Each share of Series E Preferred Stock will convert automatically into 0.1667 shares of Common Stock upon the closing of the Issuer's initial public offering, which reflects a one-for-six reverse stock split of the Issuer's Common Stock that was effected on January 17, 2014. Pharmstandard International S.A. is a wholly owned subsidiary of Public Joint Stock Company "Pharmstandard". As the parent entity, Public Joint Stock Company "Pharmstandard" has voting and investment control over the Issuer's shares held by Pharmstandard International S.A. Exhibit Index Exhibit 24.1 - Power of Attorney /s/ Eriks Martinovskis 2014-02-06 /s/ Gerard Birchen 2014-02-06 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

         Limited Power Of Attorney For Section 16 Reporting Obligations

Know all by these presents, that the undersigned hereby makes, constitutes and
appoints each of Jeffrey D. Abbey and Lori R. Harrelson, signing singly and each
acting individually, as the undersigned's true and lawful attorney-in-fact with
full power and authority as hereinafter described to:

        (1)     execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of, and/or holder
of equity in, Argos Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

        (2)     do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to prepare, complete and
execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or
amendments thereto, and timely deliver and file such form with the United States
Securities and Exchange Commission (the "SEC") and any stock exchange or similar
authority, including without limitation the filing of a Form ID or any other
application materials to enable the undersigned to gain or maintain access to
the Electronic Data Gathering Analysis and Retrieval System of the SEC;

        (3)     seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information regarding transactions in the
Company's securities from any third party, including brokers, employee benefit
plan administrators and trustees, and the undersigned hereby authorizes any such
person to release any such information to such attorney-in-fact and approves and
ratifies any such release of information; and

        (4)     take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming nor
relieving, nor is the Company assuming nor relieving, any of the undersigned's
responsibilities to comply with Section 16 of the Exchange Act. The undersigned
acknowledges that neither the Company nor the foregoing attorneys-in-fact assume
(i) any liability for the undersigned's responsibility to comply with the
requirement of the Exchange Act, (ii) any liability of the undersigned for any
failure to comply with such requirements, or (iii) any obligation or liability
of the undersigned for profit disgorgement under Section 16(b) of the Exchange
Act.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this February 6th, 2014.

                                        PHARMSTANDARD INTERNATIONAL S.A.

                                        By: /s/ Eriks Martinovskis
                                           -----------------------------------
                                        Name: Eriks Martinovskis
                                        Title: Director

                                        By: /s/ Gerard Birchen
                                           -----------------------------------
                                        Name: Gerard Birchen
                                        Title: Director

                                     PUBLIC JOINT STOCK COMPANY "PHARMSTANDARD"

                                        By: /s/ Krylov I.K.
                                            ----------------------------------
                                        Name: Krylov I.K.
                                        Title: General Director